Aquavit Pharmaceuticals has submitted its Investigation of New Drug package (IND) for a new botulinum toxin to the FDA for approval. DTX-021 is a botulinum toxin type A drug intended for the treatment of moderate-to-severe glabellar lines. It is a highly purified and clinically tested injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. Aquavit will be initiating a long term Phase-II clinical trial after the approval of the IND. DTX-021 will be marketed as Dermatox. They will also introduce DTX-022 (to be marketed as Microtox) will be a pan-facial microinjection of neurotoxins, once FDA approved. "We are thrilled to present DTX-021 and DTX-022 programs at this year's AAD," says Sobin Chang, CEO of Aquavit. "With Aquavit's proven track record of developing and launching a global brand such as AQUAGOLD, combined with our network of physicians and knowledge of botulinum toxins, we are poised to make a significant impact in the fast-growing multi-billion dollar neurotoxin market. We plan to introduce the most innovative botulinum toxin programs to uplift and modernize the treatment paradigm."